Product identification
Medicine name:
Nobivac KC
Nobivac KC nasal drops, lyophilisate and solvent for suspension for dogs
Active substance:
- Bordetella bronchiseptica, strain B-C2, Live
- Canine parainfluenza virus, strain Cornell, Live
Target species:
-
Dog
Route of administration:
-
Nasal use
Product details
Active substance and strength:
-
Bordetella bronchiseptica, strain B-C2, Live9.70/log10 colony forming unit(s)0.40millilitre(s)
-
Canine parainfluenza virus, strain Cornell, Live5.80/log10 tissue culture infective dose 500.40millilitre(s)
Pharmaceutical form:
-
Nasal spray, lyophilisate and solvent for suspension
Withdrawal period by route of administration:
-
Nasal use
- Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI07AF
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Package description:
- Cardboard or plastic boxes with 50 glass (tiype I) vial closed with a halogenobutyl rubber stopper and aluminium cap, 25 x 1 dose of vaccine and solvent
- Cardboard or plastic boxes with 10 glass (tiype I) vial closed with a halogenobutyl rubber stopper and aluminium cap, 5 x 1 dose of vaccine and solvent
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application (Article 12(3) of Directive No 2001/82/EC)
Manufacturing sites for batch release:
- INTERVET INTERNATIONAL B.V.
Authorisation number:
- 668/00DGV
Date of authorisation status change:
Reference member state:
-
Italy
Procedure number:
- IT/V/0134/001
Concerned member states:
-
Austria
-
Belgium
-
Denmark
-
Finland
-
France
-
Germany
-
Greece
-
Ireland
-
Luxembourg
-
Netherlands
-
Norway
-
Poland
-
Portugal
-
Romania
-
Spain
-
Sweden
-
United Kingdom (Northern Ireland)
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Combined File of all Documents
English (PDF)
Download Published on: 13/02/2024